Search

Your search keyword '"Zureikat, Amer H."' showing total 1,155 results
Start Over Author "Zureikat, Amer H."
1,155 results on '"Zureikat, Amer H."'

202. Hepatic Arterial Infusion in Combination with Modern Systemic Chemotherapy is Associated with Improved Survival Compared with Modern Systemic Chemotherapy Alone in Patients with Isolated Unresectable Colorectal Liver Metastases: A Case–Control Study

Author

Dhir, Mashaal, Jones, Heather L., Shuai, Yongli, Clifford, Amber K., Perkins, Samantha, Steve, Jennifer, Hogg, Melissa E., Choudry, M. Haroon A., Pingpank, James F., Holtzman, Matthew P., Zeh, III, Herbert J., Bahary, Nathan, Bartlett, David L., and Zureikat, Amer H.

Published
2017
Full Text
View/download PDF

207. Robotic-Assisted Minimally Invasive Pancreaticoduodenectomy: Is Laparoscopy Still Justified? A Study on National Trends and Outcomes from the American College of Surgeons NSQIP

Author

Khachfe, Hussein H, primary, Nassour, Ibrahim, additional, Hammad, Abdulrahman, additional, AlMasri, Samer, additional, Hodges, Jacob C, additional, Liu, Hao, additional, Lee, Kenneth K W, additional, Pitt, Henry A, additional, Zureikat, Amer H, additional, and Paniccia, Alessandro, additional

Published
2022
Full Text
View/download PDF

209. Pancreaticoduodenectomy for benign and premalignant pancreatic and ampullary disease: is robotic surgery the better approach?

Author

Mungo, Benedetto, primary, Hammad, Abdulrahman, additional, AlMasri, Samer, additional, Dogeas, Epameinondas, additional, Nassour, Ibrahim, additional, Singhi, Aatur D., additional, Zeh, Herbert J., additional, Hogg, Melissa E., additional, Lee, Kenneth K. W., additional, Zureikat, Amer H., additional, and Paniccia, Alessandro, additional

Published
2022
Full Text
View/download PDF

225. Robotic Pancreaticoduodenectomy: Increased Adoption and Improved Outcomes - Is Laparoscopy Still Justified?

Author

Khachfe, Hussein H., primary, Nassour, Ibrahim, additional, Hammad, Abdulrahman Y., additional, Hodges, Jacob C., additional, AlMasri, Samer, additional, Liu, Hao, additional, deSilva, Anissa, additional, Kraftician, Jasmine, additional, Lee, Kenneth K., additional, Pitt, Henry A., additional, Zureikat, Amer H., additional, and Paniccia, Alessandro, additional

Published
2022
Full Text
View/download PDF

228. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study

Author

Janssen, Quisette P., primary, van Dam, Jacob L., additional, Prakash, Laura R., additional, Doppenberg, Deesje, additional, Crane, Christopher H., additional, van Eijck, Casper H.J., additional, Ellsworth, Susannah G., additional, Jarnagin, William R., additional, O’Reilly, Eileen M., additional, Paniccia, Alessandro, additional, Reyngold, Marsha, additional, Besselink, Marc G., additional, Katz, Matthew H.G., additional, Tzeng, Ching-Wei D., additional, Zureikat, Amer H., additional, Groot Koerkamp, Bas, additional, Wei, Alice C., additional, and _, _, additional

Published
2022
Full Text
View/download PDF

229. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer

Author

AlMasri, Samer, primary, Zenati, Mazen, additional, Hammad, Abdulrahman, additional, Nassour, Ibrahim, additional, Liu, Hao, additional, Hogg, Melissa E., additional, Zeh, Herbert J., additional, Boone, Brian, additional, Bahary, Nathan, additional, Singhi, Aatur D., additional, Lee, Kenneth K., additional, Paniccia, Alessandro, additional, and Zureikat, Amer H., additional

Published
2022
Full Text
View/download PDF

230. Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study.

Author

Murthy, Pranav, primary, Li, Kelvin, additional, Anderko, Renee R., additional, Singhi, Aatur D., additional, DeSilva, Annissa, additional, Chopra, Asmita, additional, Hammad, Abdulraham Y., additional, Paniccia, Alessandro, additional, Morris, Alison, additional, Lee, Kenneth K., additional, Mailliard, Robbie B., additional, Lotze, Michael T., additional, Methe, Barbara, additional, and Zureikat, Amer H., additional

Published
2022
Full Text
View/download PDF

232. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium

Author

Janssen, Quisette P, van Dam, Jacob L, Doppenberg, Deesje, Prakash, Laura R, van Eijck, Casper H J, Jarnagin, William R, O' Reilly, Eileen M, Paniccia, Alessandro, Besselink, Marc G, Katz, Matthew H G, Tzeng, Ching-Wei D, Wei, Alice C, Zureikat, Amer H, Groot Koerkamp, Bas, Surgery, Graduate School, CCA - Cancer Treatment and Quality of Life, and AGEM - Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Cancer Research, Leucovorin, Editorials, Adenocarcinoma, Irinotecan, Neoadjuvant Therapy, Cohort Studies, Oxaliplatin, Pancreatic Neoplasms, Oncology, SDG 3 - Good Health and Well-being, Antineoplastic Combined Chemotherapy Protocols, Humans, Fluorouracil, Carcinoma, Pancreatic Ductal, Retrospective Studies
Abstract

Background Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to provide realistic estimates of oncologic outcomes in these patients. Methods This international retrospective cohort study included all consecutive patients presenting with localized PDAC who received at least 1 cycle of (m)FOLFIRINOX as initial treatment in 5 referral centers from the United States and the Netherlands (2012-2019). Primary outcome was median overall survival (OS), calculated from the date of tissue diagnosis, assessed using Kaplan-Meier estimates. Log-rank test was used to compare OS between groups. A Cox proportional hazards regression model was used to assess prognostic baseline factors for OS. All statistical tests were 2-sided. Results Overall, 1835 patients were included, of whom 958 (52.2%) had locally advanced (LA), 531 (28.9%) had borderline resectable (BR), and 346 (18.9%) had potentially resectable (PR) PDAC. The median number of (m)FOLFIRINOX cycles was 6 (interquartile range = 4-8). Subsequent treatment included second chemotherapy (12.9%), radiotherapy (49.0%), and resection (37.9%). The resection rate was 17.6% for LA, 53.1% for BR, and 70.5% for PR PDAC (P 1 mm) was 55.2% for LA, 62.6% for BR, and 79.2% for PR PDAC (P 500 U/mL, and body mass index ≤18.5 kg/m2. Conclusions This large international cohort study provides realistic estimates of resection rates and survival in patients with LA, BR, and PR PDAC who started (m)FOLFIRINOX treatment in PDAC referral centers.

Published
2022

233. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma:A TAPS Consortium Study

Author

Janssen, Quisette P., van Dam, Jacob L., Prakash, Laura R., Doppenberg, Deesje, Crane, Christopher H., van Eijck, Casper H.J., Ellsworth, Susannah G., Jarnagin, William R., O'Reilly, Eileen M., Paniccia, Alessandro, Reyngold, Marsha, Besselink, Marc G., Katz, Matthew H.G., Tzeng, Ching Wei D., Zureikat, Amer H., Groot Koerkamp, Bas, Wei, Alice C., Janssen, Quisette P., van Dam, Jacob L., Prakash, Laura R., Doppenberg, Deesje, Crane, Christopher H., van Eijck, Casper H.J., Ellsworth, Susannah G., Jarnagin, William R., O'Reilly, Eileen M., Paniccia, Alessandro, Reyngold, Marsha, Besselink, Marc G., Katz, Matthew H.G., Tzeng, Ching Wei D., Zureikat, Amer H., Groot Koerkamp, Bas, and Wei, Alice C.

Abstract

Background: The value of neoadjuvant radiotherapy (RT) after 5-fluo-rouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain. Methods: We conducted an international retrospective cohort study including consecutive patients with BR PDAC who received (m)FOLFIRINOX as initial treatment (2012-2019) from the TransAtlantic Pancreatic Surgery Consortium. Because the decision to administer RT is made after chemotherapy, patients with metastases or deterioration after (m)FOLFIRINOX or a performance score $2 were excluded. Patients who received RT after (m)FOLFIRINOX were matched 1:1 by nearest neighbor propensity scores with patients who did not receive RT. Propensity scores were calculated using sex, age (#70 vs.70 years), WHO performance score (0 vs 1), tumor size (0-20 vs 21-40 vs.40 mm), tumor location (head/uncinate vs body/tail), number of cycles (1-4 vs 5-8 vs.8), and baseline CA 19-9 level (#500 vs.500 U/mL). Primary outcome was overall survival (OS) from diagnosis. Results: Of 531 patients who received neoadjuvant (m)FOLFIRINOX for BR PDAC, 424 met inclusion criteria and 300 (70.8%) were propensity score-matched. After matching, median OS was 26.2 months (95% CI, 24.0-38.4) with RT versus 32.8 months (95% CI, 25.3-42.0) without RT (P5.71). RT was associated with a lower resection rate (55.3% vs 72.7%; P5.002). In patients who underwent a resection, RT was associated with a comparable margin-negative resection rate (.1 mm) (70.6% vs 64.8%; P5.51), more node-negative disease (57.3% vs 37.6%; P5.01), and more major pathologic response with,5% tumor viability (24.7% vs 8.3%; P5.006). The OS associated with conventional and stereotactic body RT approaches was similar (median OS, 25.7 vs 26.0 months; P5.92). Conclusions: In patients with BR PDAC, neoadjuvant RT following (m)FOLFIRINOX was associated with more node-negative

Published
2022

234. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma:A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium

Author

Janssen, Quisette P, van Dam, Jacob L, Doppenberg, Deesje, Prakash, Laura R, van Eijck, Casper H J, Jarnagin, William R, O' Reilly, Eileen M, Paniccia, Alessandro, Besselink, Marc G, Katz, Matthew H G, Tzeng, Ching-Wei D, Wei, Alice C, Zureikat, Amer H, Groot Koerkamp, Bas, Janssen, Quisette P, van Dam, Jacob L, Doppenberg, Deesje, Prakash, Laura R, van Eijck, Casper H J, Jarnagin, William R, O' Reilly, Eileen M, Paniccia, Alessandro, Besselink, Marc G, Katz, Matthew H G, Tzeng, Ching-Wei D, Wei, Alice C, Zureikat, Amer H, and Groot Koerkamp, Bas

Abstract

BACKGROUND: Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking. This study aimed to provide realistic estimates of oncologic outcomes in these patients.METHODS: This international retrospective cohort study included all consecutive patients presenting with localized PDAC who received at least 1 cycle of (m)FOLFIRINOX as initial treatment in 5 referral centers from the United States and the Netherlands (2012-2019). Primary outcome was median overall survival (OS), calculated from the date of tissue diagnosis, assessed using Kaplan-Meier estimates. Log-rank test was used to compare OS between groups. A Cox proportional hazards regression model was used to assess prognostic baseline factors for OS. All statistical tests were 2-sided.RESULTS: Overall, 1835 patients were included, of whom 958 (52.2%) had locally advanced (LA), 531 (28.9%) had borderline resectable (BR), and 346 (18.9%) had potentially resectable (PR) PDAC. The median number of (m)FOLFIRINOX cycles was 6 (interquartile range = 4-8). Subsequent treatment included second chemotherapy (12.9%), radiotherapy (49.0%), and resection (37.9%). The resection rate was 17.6% for LA, 53.1% for BR, and 70.5% for PR PDAC (P < .001). The margin-negative resection rate (>1 mm) was 55.2% for LA, 62.6% for BR, and 79.2% for PR PDAC (P < .001). The median OS was 18.7 months (95% confidence interval [CI] = 17.7 to 19.9 months) for LA, 23.2 months (95% CI = 21.0 to 25.7 months) for BR, and 31.2 months (95% CI = 26.2 to 36.6 months) for PR PDAC (P < .001). The median OS for 695 patients who underwent a resection was 38.3 months (95% CI = 36.1 to 42.0 months). Independent prognostic factors at baseline for worse OS were more advanced stage, worse performance status, baseline carbohydrate antigen (CA) 19-9 > 500 U/mL, and body mass index ≤1

Published
2022

235. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size

Author

Pathologie Groep Brosens, Cancer, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Hackeng, Wenzel M, Brosens, Lodewijk A A, Kim, Joo Young, O'Sullivan, Roderick, Sung, You-Na, Liu, Ta-Chiang, Cao, Dengfeng, Heayn, Michelle, Brosnan-Cashman, Jacqueline, An, Soyeon, Morsink, Folkert H M, Heidsma, Charlotte M, Valk, Gerlof D, Vriens, Menno R, Nieveen van Dijkum, Els, Offerhaus, G Johan A, Dreijerink, Koen M A, Zeh, Herbert, Zureikat, Amer H, Hogg, Melissa, Lee, Kenneth, Geller, David, Marsh, J Wallis, Paniccia, Alessandro, Ongchin, Melanie, Pingpank, James F, Bahary, Nathan, Aijazi, Muaz, Brand, Randall, Chennat, Jennifer, Das, Rohit, Fasanella, Kenneth E, Khalid, Asif, McGrath, Kevin, Sarkaria, Savreet, Singh, Harkirat, Slivka, Adam, Nalesnik, Michael, Han, Xiaoli, Nikiforova, Marina N, Lawlor, Rita Teresa, Mafficini, Andrea, Rusev, Boris, Corbo, Vincenzo, Luchini, Claudio, Bersani, Samantha, Pea, Antonio, Cingarlini, Sara, Landoni, Luca, Salvia, Roberto, Milione, Massimo, Milella, Michele, Scarpa, Aldo, Hong, Seung-Mo, Heaphy, Christopher M, Singhi, Aatur D, Pathologie Groep Brosens, Cancer, Pathologie Pathologen staf, Pathologie, MS Endocriene Oncologie, Heelkunde Opleiding, MS CGO, Hackeng, Wenzel M, Brosens, Lodewijk A A, Kim, Joo Young, O'Sullivan, Roderick, Sung, You-Na, Liu, Ta-Chiang, Cao, Dengfeng, Heayn, Michelle, Brosnan-Cashman, Jacqueline, An, Soyeon, Morsink, Folkert H M, Heidsma, Charlotte M, Valk, Gerlof D, Vriens, Menno R, Nieveen van Dijkum, Els, Offerhaus, G Johan A, Dreijerink, Koen M A, Zeh, Herbert, Zureikat, Amer H, Hogg, Melissa, Lee, Kenneth, Geller, David, Marsh, J Wallis, Paniccia, Alessandro, Ongchin, Melanie, Pingpank, James F, Bahary, Nathan, Aijazi, Muaz, Brand, Randall, Chennat, Jennifer, Das, Rohit, Fasanella, Kenneth E, Khalid, Asif, McGrath, Kevin, Sarkaria, Savreet, Singh, Harkirat, Slivka, Adam, Nalesnik, Michael, Han, Xiaoli, Nikiforova, Marina N, Lawlor, Rita Teresa, Mafficini, Andrea, Rusev, Boris, Corbo, Vincenzo, Luchini, Claudio, Bersani, Samantha, Pea, Antonio, Cingarlini, Sara, Landoni, Luca, Salvia, Roberto, Milione, Massimo, Milella, Michele, Scarpa, Aldo, Hong, Seung-Mo, Heaphy, Christopher M, and Singhi, Aatur D

Published
2022

238. Robotic Surgery for Benign Duodenal Tumors

Author

Downs-Canner, Stephanie, Van der Vliet, Wald J., Thoolen, Stijn J. J., Boone, Brian A., Zureikat, Amer H., Hogg, Melissa E., Bartlett, David L., Callery, Mark P., Kent, Tara S., Zeh, Herbert J., and Moser, A. James

Published
2015
Full Text
View/download PDF

242. 748: DEFINING EFFECTIVE NEOADJUVANT CHEMOTHERAPY (NAC) IN PDAC, IMPLICATIONS FROM SURVIVAL AND PATTERN OF FAILURE IN PATIENTS WHO RECEIVED NAC

Author

Liu, Hao, primary, D'Alesio, Mark, additional, AlMasri, Samer, additional, Hammad, Abdulrahman Y., additional, deSilva, Annissa, additional, Rieser, Caroline, additional, Ashwat, Eishan, additional, Hampton, Erica D., additional, Lebowitz, Steven, additional, Khachfe, Hussein H., additional, Singhi, Aatur, additional, Bahary, Nathan, additional, Lee, Kenneth, additional, Zureikat, Amer H., additional, and Paniccia, Alessandro, additional

Published
2022
Full Text
View/download PDF

243. 1038: THE USE OF ANGIOTENSIN SYSTEM INHIBITOR IN THE SURVIVAL OF RESECTED PANCREATIC ADENOCARCINOMA PATIENTS

Author

Liu, Hao, primary, Nassour, Ibrahim, additional, Lebowitz, Steven, additional, D'Alesio, Mark, additional, Hampton, Erica D., additional, deSilva, Annissa, additional, Hammad, Abdulrahman Y., additional, AlMasri, Samer, additional, Khachfe, Hussein H., additional, Singhi, Aatur, additional, Bahary, Nathan, additional, Lee, Kenneth, additional, Zureikat, Amer H., additional, and Paniccia, Alessandro, additional

Published
2022
Full Text
View/download PDF

246. Reduction in postoperative opioid requirement associated with use of the NSS-2® Bridge device, a disposable auriculo-nerve field stimulator, and factors affecting the response in cancer patients undergoing abdominal surgical procedures

Author

Chelly, Jacques E., primary, Holtzman, Matthew P., additional, Bartlett, David L., additional, Choudry, Haroon A., additional, Pingpank, James F., additional, Zureikat, Amer H., additional, Norton, Brittany E., additional, Sadhasivam, Senthilkumar K., additional, and Vogt, Keith M., additional

Published
2022
Full Text
View/download PDF

247. Grading Pancreatic Neuroendocrine Tumors via Endoscopic Ultrasound-guided Fine Needle Aspiration

Author

Javed, Ammar A., primary, Pulvirenti, Alessandra, additional, Razi, Samrah, additional, Zheng, Jian, additional, Michelakos, Theodoros, additional, Sekigami, Yurie, additional, Thompson, Elizabeth, additional, Klimstra, David S., additional, Deshpande, Vikram, additional, Singhi, Aatur D., additional, Weiss, Matthew J., additional, Wolfgang, Christopher L., additional, Cameron, John L., additional, Wei, Alice C., additional, Zureikat, Amer H., additional, Ferrone, Cristina R., additional, and He, Jin, additional

Published
2022
Full Text
View/download PDF

248. Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer

Author

Chuckran, Christopher A., primary, Cillo, Anthony R., additional, Moskovitz, Jessica, additional, Overacre-Delgoffe, Abigail, additional, Somasundaram, Ashwin S., additional, Shan, Feng, additional, Magnon, Grant C., additional, Kunning, Sheryl R., additional, Abecassis, Irina, additional, Zureikat, Amer H., additional, Luketich, James, additional, Pennathur, Arjun, additional, Sembrat, John, additional, Rojas, Mauricio, additional, Merrick, Daniel T., additional, Taylor, Sarah E., additional, Orr, Brian, additional, Modugno, Francesmary, additional, Buckanovich, Ron, additional, Schoen, Robert E., additional, Kim, Seungwon, additional, Duvvuri, Umamaheswar, additional, Zeh, Herbert, additional, Edwards, Robert, additional, Kirkwood, John M., additional, Coffman, Lan, additional, Ferris, Robert L., additional, Bruno, Tullia C., additional, and Vignali, Dario A. A., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results